Paolo Giovanelli
Research Subjects
Paolo Giovanelli has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Juan R. Cubillos-Ruiz
Weill Cornell Medicine
25 shared publications - Tito Alejandro Sandoval
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, USA
25 shared publications - Camilla Salvagno
Associate Professor of Microbiology and Immunology Well Cornell Medicine New York NY
24 shared publications - Chang-Suk Chae
Associate Professor of Microbiology and Immunology Well Cornell Medicine New York NY
24 shared publications - Deepika Awasthi
Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY 10065, USA
24 shared publications - Dmitriy Zamarin
Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
24 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S3 contains all statistically significant DEGs from RNAseq data
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S3 contains all statistically significant DEGs from RNAseq data
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S5 contains all the primers used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S5 contains all the primers used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S1 describes all the human ascites samples analyzed
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S1 describes all the human ascites samples analyzed
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S4 describes the organoids used in this study
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S4 describes the organoids used in this study
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Figure S1. (a) Effect of dietary iron levels on ovarian cancer progression. Figure S2. Flow cytometry gating strategy for the analysis of peritoneal cells from mice bearing ID8Defb29/Vegfa tumors that were treated with deferiprone as single agent or in combination with cisplatin. Figure S3. (a-f) Wild-type female mice were implanted with ID8-Defb29/Vegfa tumors and treated as described in Fig 2 d. Figure S4. (a) Representative images of NKp46 staining on the entire omentum. Figure S5. (a) MTT assays for ID8-Defb29/Vegfa, PPNM, and MP cells treated with different concentrations of deferiprone for 12, 24, and 48 hours. Figure S6. (a) Human ovarian cancer cell lines were treated with deferiprone for 48 hours and expression of the indicated genes was analyzed by qRT-PCR. Colors indicate fold change (FC) upon deferiprone treatment compared with vehicle control. Figure S7. (a-b) Mitochondrial iron was traced using mito-ferrogreen in iron-overloaded ID8-Defb29/Vegfa cells that were exposed to deferiprone (100 µM) or vehicle control. Figure S8. (a) Schematic representation of treatment regimens under IFNAR1 blockade related to Fig. 6 a-c.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Figure S1. (a) Effect of dietary iron levels on ovarian cancer progression. Figure S2. Flow cytometry gating strategy for the analysis of peritoneal cells from mice bearing ID8Defb29/Vegfa tumors that were treated with deferiprone as single agent or in combination with cisplatin. Figure S3. (a-f) Wild-type female mice were implanted with ID8-Defb29/Vegfa tumors and treated as described in Fig 2 d. Figure S4. (a) Representative images of NKp46 staining on the entire omentum. Figure S5. (a) MTT assays for ID8-Defb29/Vegfa, PPNM, and MP cells treated with different concentrations of deferiprone for 12, 24, and 48 hours. Figure S6. (a) Human ovarian cancer cell lines were treated with deferiprone for 48 hours and expression of the indicated genes was analyzed by qRT-PCR. Colors indicate fold change (FC) upon deferiprone treatment compared with vehicle control. Figure S7. (a-b) Mitochondrial iron was traced using mito-ferrogreen in iron-overloaded ID8-Defb29/Vegfa cells that were exposed to deferiprone (100 µM) or vehicle control. Figure S8. (a) Schematic representation of treatment regimens under IFNAR1 blockade related to Fig. 6 a-c.
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (111) , eadz6869
Enkephalin-producing regulatory T cells in the skin restrain local inflammation through control of nociception
The skin integrates diverse signals discerned by sensory neurons and immune cells to elicit adaptive responses to a range of stresses. Considering interactions between nervous and immune systems, we examined whether regulatory T (T reg ) cells, which suppress systemic and local inflammation, can modulate activation of peripheral neurons. Acute T reg cell “loss of function” increased neuronal activation to noxious stimuli independently of their immunosuppressive function. This activity was mediated by a T reg cell subset capable of production of enkephalins encoded by the gene Penk , whose expression is facilitated by combined TCR and glucocorticoid receptor signaling. Punctual selective depletion of Penk -expressing T reg cells or specific ablation of Penk in T reg cells increased neuronal activation in response to noxious stimuli and associated inflammation. Our study indicates that a population of tissular T reg cells exhibits neuromodulatory activity to restrain local inflammation in the skin.
- 5 September 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (111) , eadz6869
Enkephalin-producing regulatory T cells in the skin restrain local inflammation through control of nociception
The skin integrates diverse signals discerned by sensory neurons and immune cells to elicit adaptive responses to a range of stresses. Considering interactions between nervous and immune systems, we examined whether regulatory T (T reg ) cells, which suppress systemic and local inflammation, can modulate activation of peripheral neurons. Acute T reg cell “loss of function” increased neuronal activation to noxious stimuli independently of their immunosuppressive function. This activity was mediated by a T reg cell subset capable of production of enkephalins encoded by the gene Penk , whose expression is facilitated by combined TCR and glucocorticoid receptor signaling. Punctual selective depletion of Penk -expressing T reg cells or specific ablation of Penk in T reg cells increased neuronal activation in response to noxious stimuli and associated inflammation. Our study indicates that a population of tissular T reg cells exhibits neuromodulatory activity to restrain local inflammation in the skin.
- Open Access
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S2 contains all the information related to mass spectrometry
- Open Access
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S1 describes all the human ascites samples analyzed
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S1 describes all the human ascites samples analyzed
- Open Access
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Table S5 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S5 contains all the primers used in this study
- 21 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Iron Chelation Therapy Elicits Innate Immune Control of Metastatic Ovarian Cancer
Table S5 contains all the primers used in this study